Dihydroergotoxine: 6-Mg versus 3-Mg Dosage in the Treatment of Senile Dementia. Preliminary Report*
- 1 February 1979
- journal article
- research article
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 27 (2) , 80-82
- https://doi.org/10.1111/j.1532-5415.1979.tb03345.x
Abstract
In 14 patients with senile dementia, a study was made of 2 dosage levels (3 mg or 6 mg daily) of dihydroergotoxine mesylate (DEM, Hydergine). Only a nonstatistically significant trend was found for superiority of the higher dosage. One patient showed remarkable clinical improvement during the 6-mg period; the mechanism remains unexplained. Further studies are needed with this higher dosage in less impaired patients and in those with well-defined cerebral pathologic changes.This publication has 3 references indexed in Scilit:
- Vasodilators in Senile DementiasArchives of General Psychiatry, 1979
- Selective Cyclic Nucleotide Phosphodiesterase Inhibitors as Potential Therapeutic AgentsAnnual Review of Pharmacology and Toxicology, 1977
- An Ergot Alkaloid Preparation (Hydergine) in the Treatment of Dementia: Critical Review of the Clinical LiteratureJournal of the American Geriatrics Society, 1976